Search research articles
Contact Us
Filters
Showing results (41-50 of 122) with videos related to
Page
of 13
Sort By:
Blood
|
February 3, 2009
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
Stefan Knop, Christian Gerecke, Peter Liebisch, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 20, 2019
Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
Anthony S Stein, Hagop Kantarjian, Nicola Gökbuget, et al.
Cancer
|
November 3, 2020
Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab
Max S Topp, Nicola Gökbuget, Gerhard Zugmaier, et al.
Cancer Research
|
November 17, 2006
CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells
Claudia M Kowolik, Max S Topp, Sergio Gonzalez, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
May 16, 2019
Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11
Johannes Duell, Dragana S Lukic, Margarete Karg, et al.
Blood
|
October 24, 2002
T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect
Laurence J N Cooper, Max S Topp, Lisa Marie Serrano, et al.
Hematological Oncology
|
March 21, 2022
Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group
Dennis A Eichenauer, Ina Bühnen, Annette Plütschow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2017
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study
Giovanni Martinelli, Nicolas Boissel, Patrice Chevallier, et al.
Cancer
|
May 5, 2016
Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies
Hagop M Kantarjian, Anthony S Stein, Ralf C Bargou, et al.
Haematologica
|
January 14, 2017
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia
Nicola Gökbuget, Gerhard Zugmaier, Matthias Klinger, et al.
Page
of 13
Search research articles
Search
Showing results (41-50 of 122) with videos related to
Sort By:
Page
of 13
Blood
|
February 3, 2009
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
Stefan Knop, Christian Gerecke, Peter Liebisch, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 20, 2019
Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
Anthony S Stein, Hagop Kantarjian, Nicola Gökbuget, et al.
Cancer
|
November 3, 2020
Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab
Max S Topp, Nicola Gökbuget, Gerhard Zugmaier, et al.
Cancer Research
|
November 17, 2006
CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells
Claudia M Kowolik, Max S Topp, Sergio Gonzalez, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
May 16, 2019
Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11
Johannes Duell, Dragana S Lukic, Margarete Karg, et al.
Blood
|
October 24, 2002
T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect
Laurence J N Cooper, Max S Topp, Lisa Marie Serrano, et al.
Hematological Oncology
|
March 21, 2022
Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group
Dennis A Eichenauer, Ina Bühnen, Annette Plütschow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2017
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study
Giovanni Martinelli, Nicolas Boissel, Patrice Chevallier, et al.
Cancer
|
May 5, 2016
Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies
Hagop M Kantarjian, Anthony S Stein, Ralf C Bargou, et al.
Haematologica
|
January 14, 2017
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia
Nicola Gökbuget, Gerhard Zugmaier, Matthias Klinger, et al.
Page
of 13